EICHOR
● Completed
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
Condition: Secondary Hyperparathyroidism · End Stage Kidney Disease · Sponsor: Pathalys Pharma
About this study
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they will receive dose-titrated PLS240 for an additional 26 weeks. Throughout the duration of the study, patients will be expected to attend multiple study visits where an investigator will collect blood, preform electrocardiograms (ECGs) and physical exams, and further assess the safety and efficacy of PLS240.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (68)
| Site Number: USA039-2 | Anaheim, California, United States | — |
| Site Number: USA001-2 | Chula Vista, California, United States | — |
| Site Number: USA020-2 | Escondido, California, United States | — |
| Site Number: USA042-2 | Fresno, California, United States | — |
| Site Number: USA034-2 | Fullerton, California, United States | — |
| Site Number: USA046-2 | Glendale, California, United States | — |
| Site Number: USA019-2 | Granada Hills, California, United States | — |
| Site Number: USA005-2 | La Mesa, California, United States | — |
| Site Number: USA044-2 | Lancaster, California, United States | — |
| Site Number: USA030-2 | Los Angeles, California, United States | — |
| Site Number: USA043-2 | Los Angeles, California, United States | — |
| Site Number: USA022-2 | Moorpark, California, United States | — |
+ 56 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05836220